Search

Sepsis causes injury to the intestinal mucosa, bacterial translocation, and worsens intestinal and distant organ injury. Herein, we harvested fecal samples from the sepsis group and the healthy group. Intestinal microbiota 16sRNA sequencing of the fecal samples revealed that sepsis destroyed the imbalance in intestinal microbiota. More recently, there is a growing interest in the link between lipid metabolism and disease. Fecal metabolome analysis has identified four differentially lipid metabolized compounds: PE(O-16:0/0:0), PE(17:0/0:0), PE(0:0/14:0), and PE(12:0/20:5(5Z,8Z,11Z,14Z,17Z)). Subsequently, we found that the relative abundanceof PE(0:0/14:0) was lower in the sepsis group compared with the healthy group. In vitro and in vivoexperimentations were finally used to demonstrated that PE(0:0/14:0) treatment protected against sepsis-induced damage to the intestinal barrier. Collectively, these findings provided new insight into enhanced therapy and/or preventative measures against sepsis-induced damage to the intestinal barrier.

Background: Renal clear cell carcinoma is the main type of kidney cancer and its prognosis is poor. The role of cuproptosis as an emerging tumor treatment modality in renal clear cell carcinoma is still unclear. Therefore, it is urgent to discover new prognostic markers and the role of Cuproptosis in renal cancer. Method: The source of cuproptosis-related genes was collected from the reported study from PubMed. RNA expression data and the clinical information of the corresponding patient were obtained from The Cancer Genome Atlas (TCGA) database. We randomly split the whole case into training and testing cohorts. We used three different regression analyses to confirm that lncRNAs with prognostic relevance of KIRC in the training cohort. The test cohort and the whole cohort were also included in the regression analysis to prove the accuracy of the model. eventually, a nomogram on account of clinical characteristics as well as risk scores was constructed to predict survival KIRC. Result: 119 lncRNAs linked to overall survival were gained by univariate cox regression analysis. Furthermore, to further screen for prognosis-related lncRNAs and to optimize the signature, 119 genes were included in LASSO regression as well as multifactorial Cox regression analysis. A new prognostic predictive risk profile containing four lncRNA was produced. Kaplan-Meier (KM) curve showed that patients in the high-risk group showed poor survival in all three components. The area under the curves (AUCs) for 1 year calculated from the roc curve for the three components is 0.754, 0.698, and 0.743. 0.721 and 0. 753. Moreover, the nomogram allows the calculation of 1-, 3-, and 5-year survival rates for patients with renal clear cell carcinoma. Conclusion: A new prognostic signature with four CRLs (MYG1-AS1, MELTF-AS1, AL161782.1, AC112220.2) have significant prognostic value for KIRC was conducted. It may provide a new therapeutic treatment for KIRC patients in the clinical.

BACKGROUND: Urinary pan-cancer system is a general term for tumors of the urinary system including renal cell carcinoma (RCC), prostate cancer (PRAD), and bladder cancer (BLCA). Their location, physiological functions, and metabolism are closely related, making the occurrence and outcome of these tumors highly similar. Cuproptosis is a new type of cell death that is different from apoptosis and plays an essential role in tumors. Therefore, it is necessary to study the molecular mechanism of cuproptosis-related lncRNAs to urinary system pan-cancer for the prognosis, clinical diagnosis, and treatment of urinary tumors. METHOD: In our study, we identified 35 co-expression cuproptosis-related lncRNAs (CRLs) from the urinary pan-cancer system. 28 CRLs were identified as prognostic-related CRLs by univariate Cox regression analysis. Then 11 CRLs were obtained using lasso regression and multivariate cox analysis to construct a prognostic model. We divided patients into high and low-risk groups based on the median risk scores. Next, Kaplan-Meier analysis, principal component analysis (PCA), functional rich annotations, and nomogram were used to compare the differences between the high and low-risk groups. Finally, the prediction of tumor immune dysfunction and rejection, gene mutation, and drug sensitivity were discussed. CONCLUSION: Finally, the candidate molecules of the urinary system pan-cancer were identified. This CRLs risk model may be promising for clinical prediction of prognosis and immunotherapy response in urinary system pan-cancer patients.

2′-5′-oligoadenylate synthetases (OAS) family is interferon (IFN) -induced antiviral enzymes including OAS1, OAS2, OAS3, and OAS-like (OASL) is increasingly thought to play significant roles in human cancers. This study aims to explore the potential role of OAS family genes with a new clue to providing insights on tumor immune mechanisms implicated here. High expression levels of OAS family gene were observed in most cancer types. OAS family gene expression in tumor samples correlated with poor overall survival in several cancers such as Brain Lower Grade Glioma (LGG). OAS family genes were associated with M1 macrophages in cancers. Tumor mutation burden (TMB), microsatellite instability (MSI) correlated with OAS family genes dysregulation in cancers. OAS1/OAS3/OASL is a promising target for AP-26113, and OAS2/OASL is more likely to be an effective target for itraconazole. OAS1 and OASL were significantly correlated with their pathological stages in KIRC. OAS family genes were positively correlated with M1 macrophages. Gene set enrichment analysis (GSEA ) results demonstrated OAS1/OAS2/OASL have pathways commonly associated with immunity in KIRC such as natural killer cell mediated cytotoxicity. Our study suggests that OAS family genes may influence cancer development, particularly KIRC, by modulating M1 macrophages and NK cells.

Venous thromboembolism (VTE) is one of the major complications of digestive system cancer, and coagulation-fibrinolysis genes play an important role in VTE. We used univariate Cox analysis, least absolute shrinkage and selection operator (LASSO), and multivariate Cox analysis to construct 3-PCFGs (prognostic coagulation-fibrinolysis genes) model based on six prognostic coagulation-fibrinolysis genes. Gene set enrichment analysis (GSEA) was used to analyze the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways of the high- and low-risk groups. In addition, we classified digestive system pancancer patients into three clusters A, B, and C based on 3-PCFGs by K means. High-risk group and cluster C were associated with poor prognosis in digestive system pancancer. The m6A-related genes ALKBH5, FTO, RBM15, YTHDC1, and YTHDC2 (P6A epigenetic modification and immune microenvironment components in the digestive system pancancer.

Tuberculosis is a serious disease with high morbidity and mortality, thus rapid and cost-effective diagnostic test for Mycobacterium tuberculosis (MTB) is urgently needed. Here, a novel detection diagnostic technique, termed as loop-mediated isothermal amplification label-based nanoparticles with lateral flow biosensor (LAMP-LFB), was developed and evaluated for rapid, reliable and objective detection of MTB. Two sets of primers, which targeted IS 6110 and IS 1081 sequences of MTB, were simultaneously designed for establishment of LAMP-LFB assay. The optimal reaction conditions of MTB-LAMP-LFB assay confirmed were 66ºC for only 50min. The analytical sensitivity of MTB-LAMP-LFB is 10fg of genomic templates in pure culture, and the detection results obtained from LFB was in conformity with agarose gel electrophoresis. No cross-reactivity with other common bacteria and non-tuberculous mycobacteria strains (NTM) was obtained. A total of 158 clinical samples were collected from presumptive 158 TB patients, were used for evaluating the feasibility of MTB-LAMP-LFB assay. Among 98 TB patients diagnosed with composite reference standard, the positive rate for MTB detection using liquid culture, Xpert MTB/RIF and LAMP-LFB were 40.0% (39/98), 50.0% (48/98), and 86.7% (85/98), respectively. Among 39 culture confirmed samples, 84.6% (33/39) cases were Xpert MTB/RIF-positive and 92.3% (36/39) were LAMP-LFB-positive. For the 59 clinically diagnosed TB cases 25.4% (15/59) and 83.0% (49/59) were Xpert MTB/RIF-positive and LAMP-LFB positive, respectively. Therefore, MTB-LAMP-LFB assay is a simple, reliable, and sensitive method for MTB detection and maybe prospective in early diagnosis of MTB.